Rockwell Medical (NASDAQ: RMTI) and Advanced Accelerator Applications (NASDAQ:AAAP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitabiliy.
This table compares Rockwell Medical and Advanced Accelerator Applications’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Advanced Accelerator Applications||-29.01%||-14.38%||-9.65%|
This is a summary of recent recommendations for Rockwell Medical and Advanced Accelerator Applications, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Advanced Accelerator Applications||0||1||4||0||2.80|
Rockwell Medical presently has a consensus target price of $8.50, suggesting a potential upside of 33.44%. Advanced Accelerator Applications has a consensus target price of $54.00, suggesting a potential upside of 10.75%. Given Rockwell Medical’s higher probable upside, equities analysts clearly believe Rockwell Medical is more favorable than Advanced Accelerator Applications.
Risk & Volatility
Rockwell Medical has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Advanced Accelerator Applications has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Insider and Institutional Ownership
20.5% of Rockwell Medical shares are owned by institutional investors. Comparatively, 40.9% of Advanced Accelerator Applications shares are owned by institutional investors. 15.9% of Rockwell Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Rockwell Medical and Advanced Accelerator Applications’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Rockwell Medical||$54.25 million||6.11||-$19.87 million||($0.42)||-15.17|
|Advanced Accelerator Applications||$135.87 million||15.82||-$14.65 million||($0.68)||-71.70|
Advanced Accelerator Applications has higher revenue and earnings than Rockwell Medical. Advanced Accelerator Applications is trading at a lower price-to-earnings ratio than Rockwell Medical, indicating that it is currently the more affordable of the two stocks.
Advanced Accelerator Applications beats Rockwell Medical on 9 of the 13 factors compared between the two stocks.
Rockwell Medical Company Profile
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.
Advanced Accelerator Applications Company Profile
Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The Company develops, produces and commercializes molecular nuclear medicine (MNM), diagnostic and therapeutic products. MNM uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases, such as cancer. The Company has a portfolio of nine diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. PET and SPECT are imaging techniques in molecular nuclear diagnostics (MND) with applications in clinical oncology, cardiology, neurology and inflammatory/infectious diseases. Its commercial products include Gluscan/Gluscan 500/Barnascan, FluoroChol, MIBITEC/Adamibi, DOPAVIEW, Leukokit, Neurolite, SomaKit and NETSPOT. Additional MND product candidates include Annexin V-128, a SPECT product candidate for the imaging of apoptotic and necrotic lesions with potential applications in a range of indications.
What are top analysts saying about Rockwell Medical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Rockwell Medical Inc. and related companies.